The US Food and Drug Administration Allergenic Products Advisory Committee this week held a meeting to discuss whether efficacy and safety data support licensure of Palforzia as a treatment to reduce the incidence and severity of allergic reactions, including anaphylaxis, after accidental exposure to peanut in patients four through 17 years of age with a confirmed diagnosis of peanut allergy.
Aimmune Therapeutics is a biopharmaceutical company developing oral treatments for potentially life-threatening food allergies.
The company's Characterized Oral Desensitization ImmunoTherapy (CODIT) approach is intended to provide meaningful levels of protection against allergic reactions resulting from exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens.
Aimmune's first, investigational, complex biologic product candidate, Palforzia (AR101), is being developed as a treatment to reduce the frequency and severity of adverse events following exposure to peanut.
The BLA for Palforzia is under review by the FDA, which granted Palforzia Breakthrough Therapy Designation in 2015 for the desensitization of peanut-allergic patients 4 to 17 years of age.
The European Medicines Agency is reviewing Aimmune's Marketing Authorization Application for Palforzia, which Aimmune submitted in June 2019.
Aimmune initiated a randomised phase 2 clinical trial of its second investigational, complex biologic product, AR201, for the treatment of egg allergy in August 2019.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial